We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Janssen-Cilag’s Drug Invokana Recommended by NICE for Type 2 Diabetes

Janssen-Cilag’s Drug Invokana Recommended by NICE for Type 2 Diabetes

July 2, 2014

The UK’s National Institute for Health and Care Excellence said it will cover Johnson & Johnson subsidiary Janssen-Cilag’s diabetes drug Invokana (canagliflozin) as a treatment for people with type 2 diabetes.

The decision, which will allow the drug to be reimbursed in the UK, recommends use of the drug in a variety of conditions, including alongside metformin when the patient can’t take a sulfonylurea or would be at significant risk of hypoglycaemia.

Carole Longson, director of NICE’s center for health technology evaluation, says the recommendation for canagliflozin adds another clinically and cost-effective option to the armory of drugs to control type 2 diabetes.

The drug becomes the tenth diabetes treatment recommended by NICE. Others are metformin, sulfonylurea, sitagliptin, vildagliptin, pioglitazone, dapagliflozin, liraglutide, exenatide, rapid-acting insulin secretagogues and insulin to help lower blood sugar levels for type 2 diabetes.

Invokana, which is from a class of drugs called sodium glucose co-transporter-2 (SGLT-2) inhibitors, received FDA approval last year. Janssen officials called the UK approval an important milestone for the drug, which was approved in Europe last year. — Jonathon Shacat

Originally appeared in Drug Industry Daily, the pharmaceutical industry’s number one source for regulatory news and information. Click here for more information.

Pharmaceuticals Regulatory Affairs Submissions and Approvals

Upcoming Events

  • 21Jan

    Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

  • 10Feb

    FDA Under the Biden Administration: What’s to Come and What It Will Mean

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Purple_Approved_Stamp.gif

    Seno Medical Gets Premarket Approval for Breast Cancer Diagnostic

  • Triple Vaccine, needles

    Moderna to Start New Trial Adding Third Shot of COVID-19 Vaccine

  • Supreme Court Rejects Merck’s Appeal for $2.5 Billion Patent Verdict Reinstatement

  • FDA clears text

    FDA Clears SCC’s Transfusion-Management Software

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing